Genmab Announces Capital Increase Following Employee Warrant Exercises

Genmab ( (GMAB) ) has provided an announcement.

Genmab A/S, the Copenhagen‑based biotechnology group specializing in antibody‑based therapies for cancer and other serious diseases, has expanded its global footprint over more than 25 years through a mix of innovative platforms and a growing portfolio of approved medicines. The company’s late‑stage clinical pipeline and international presence across North America, Europe and Asia Pacific underline its ambition to remain a leading force in next‑generation biologic treatments.

On February 24, 2026, Genmab announced a modest capital increase driven by employee warrant exercises, issuing 12,313 new shares without pre‑emption rights for existing shareholders. The transaction, which will raise roughly DKK 17.1 million and dilute existing equity by about 0.02%, takes the company’s total share capital to 64,250,721 shares and underscores the ongoing use of equity‑based incentives while having only a limited impact on the firm’s overall capital structure.

The new ordinary shares, subscribed for cash at strike prices ranging from DKK 1,147.50 to DKK 1,615.00, will carry standard voting and dividend rights from subscription and are expected to be listed on Nasdaq Copenhagen once registered with the Danish Business Authority. For investors, the move signals continued alignment of employee compensation with shareholder value creation, while leaving Genmab’s strategic and operational trajectory in antibody‑focused drug development essentially unchanged.

The most recent analyst rating on (GMAB) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.

The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, the company has built a broad portfolio of antibody-based therapeutic formats and powers eight approved antibody medicines, supported by a strong late-stage clinical pipeline across North America, Europe and Asia Pacific.

Genmab’s platform includes bispecific antibodies, antibody–drug conjugates, immune‑modulating antibodies and other next‑generation modalities. By advancing both wholly owned programs and partnered assets, the company aims to deliver transformative therapies, reinforcing its position as a key player in the global oncology and biologics markets.

Average Trading Volume: 1,672,300

Technical Sentiment Signal: Buy

Current Market Cap: $17.69B

See more insights into GMAB stock on TipRanks’ Stock Analysis page.